Jan Koski, MSc, Finnish Red Cross Blood Service, Helsinki, Finland, discusses the rationale behind developing SIRPalpha-based CARs, and highlights how these novel constructs may play a role in clinical practice. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.